ERBB2 and breast carcinoma: Given these significant benefits in PFS, overall survival, and patient-reported QoL metrics, Palbociclib remains a highly effective and recommended option for patients with HR+, HER2-advanced breast cancer, supported as a standard of care by both regulatory and clinical practice guidelines.